Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by existing investors Qingnuo Capital and Tianjin Qingzhi Technology Partnership, along with Suzhou Industrial Park Science and Technology Innovation Investment Partnership, the Institute for AI Industry Research, Tsinghua University, and Kindstar Global. The proceeds will be used for pipeline research and development and technology platform construction.
Company Background and Achievements
Carrier Bio boasts an exosome separation platform with independent intellectual property rights and multiple pipelines based on thousands of large-scale multi-center clinical studies. The company has concluded clinical studies in early blood diagnosis of Alzheimer’s disease and Parkinson’s disease, and a dynamic follow-up study on early diagnosis and treatment of tumors. These achievements highlight Carrier Bio’s commitment to advancing innovative solutions in the field of exosome technology.
Future Prospects and Strategic Use of Funds
The Series A+ financing round positions Carrier Biomed to further enhance its capabilities in exosome technology. By investing in pipeline research and development and technology platform construction, Carrier Bio aims to solidify its position as a leader in the field, addressing significant unmet medical needs and improving patient outcomes through innovative diagnostic and therapeutic solutions.-Fineline Info & Tech
